PolyPid (PYPD)
(Delayed Data from NSDQ)
$3.53 USD
-0.12 (-3.29%)
Updated Aug 2, 2024 03:58 PM ET
After-Market: $3.55 +0.02 (0.57%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
PYPD 3.53 -0.12(-3.29%)
Will PYPD be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for PYPD based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for PYPD
PolyPid Ltd. (PYPD) Upgraded to Buy: What Does It Mean for the Stock?
Wall Street Analysts Think PolyPid Ltd. (PYPD) Could Surge 206%: Read This Before Placing a Bet
PYPD: What are Zacks experts saying now?
Zacks Private Portfolio Services
Is Liquidia Technologies (LQDA) Outperforming Other Medical Stocks This Year?
All You Need to Know About PolyPid Ltd. (PYPD) Rating Upgrade to Buy
Wall Street Analysts Believe PolyPid Ltd. (PYPD) Could Rally 223%: Here's is How to Trade
Other News for PYPD
PolyPid Secures Funding, Extends Runway for D-PLEX100 Trial
PolyPid announces private placement of up to $14M in proceeds
PolyPid Ends Equity Sales Agreement, No Penalties Incurred
Buy Rating Affirmed for PolyPid’s D-PLEX100 Amid Significant Market Opportunity for Surgical Infection Prevention
PolyPid Advances Trial for Infection Prevention